Baylor College of Medicine

A study in Parkinson's disease patients with dyskinesia to assess fixed dose combinations of JM-010 (H-48387)



A Randomized, Double-blind, Placebo-Controlled, Two-Part study in Parkinson's disease patients with dyskinesia to assess the efficacy and safety/tolerability of fixed dose combinations of JM-010 and its individual components.  

The purpose of this study, which involved research, is to determine if investigational treatment, JM-010, is safe and effective in the treatment of levodopa-induced dyskinesia.  An investigational drug is one that is not approved by the United Stated Food and Drug Administration (FDA).  JM-010 has been tested previously in approximately 30 subjects with Parkinson's disease, who had developed moderate to severe dyskinesia while being treated with levodopa.  The results have shown that JM-010 reduced the severity of dyskinesia and did not significantly worsen motor symptoms of PD.  

You can be in this research study if you are

  • 18-80 years of age
  • have a PD diagnosis
  • is on a stable levodopa dosing and other anti-parkinsonism regiment
  • and is willing to stop using amantadine and/or MAOi.


Rory Mahabir

Phone 1: 713–798–5989

IRB: H-48387




Back to topback-to-top